Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adamas Pharmaceuticals IncADMS · Entity 133085 | Chief Medical Officer | April 08, 2019 | April 10, 2019 |
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 12, 2026 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | June 04, 2025 | June 06, 2025 |
| Septerna, Inc.SEPN · Entity 2452 | Chief Medical Officer | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adamas Pharmaceuticals Inc
Report date April 08, 2019 · Filed April 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,141 |
Reported balance
After 2019-04-08 transaction · row 1
1 source rowRow 1 · 2019-04-08 · Grant · Acquired 30,000 · Balance 49,141 F1: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2020, March 20, 2021, March 20, 2022 and March 20, 2023, subject to Reporting Person's Continuous Service as of each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2029-04-07 | Direct | 60,000 |
Reported balance
After 2019-04-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-08 · Grant · Acquired 60,000 · Balance 60,000 F2: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2020, March 20, 2021, March 20, 2022 and March 20, 2023, subject to Reporting Person's Continuous Service as of each such date.
F2: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
Quince Therapeutics, Inc.
Report date June 04, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2035-06-04 | Direct | 27,000 |
Reported balance
After 2025-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-04 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.
Septerna, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.37 · Expires 2036-09-07 | Direct | 275,000 |
Reported balance
After 2026-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-08 · Grant · Acquired 275,000 · Balance 275,000 F1: 25% of the shares underlying this option will vest on August 24, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option will vest on August 24, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.11 · Expires 2030-02-27 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 125,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
F2: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.
REATA PHARMACEUTICALS INC
Report date September 26, 2023 · Filed September 26, 2023
Section 16 reporting ended · disclosed 2023-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 1
1 source rowRow 1 · 2023-09-26 · Disposition to issuer · Disposed 45,000 · Balance 0 F3: The shares represent RSUs, which were to vest as to 11,250 shares on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter. F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.12 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-26 · Disposition to issuer · Disposed 90,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)
F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
F3: The shares represent RSUs, which were to vest as to 11,250 shares on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 21:08 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $37.37 | $0.00 |
DisclosureSEC source: 0001193125-26-388033 · ownership.xml · derivative · entry 1 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2036-09-07 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on August 24, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 19:08 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-26-002980 · tm262917-6_4seq1.xml · derivative · entry 1 Patni Rajiv · CIK 0001616200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 17:14 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000615 · form4.xml · derivative · entry 1 Patni Rajiv · CIK 0001616200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 08:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001104659-25-003952 · tm252892-2_4seq1.xml · derivative · entry 1 Patni Rajiv · CIK 0001616200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-01-15 F1 · derivative.exercise_date: On January 15, 2025, the Reporting Person was granted an option to purchase 44,000 shares of common stock, which vests in three equal installments on the first three anniversaries of the grant date, subject to his continued service as a Director through the vesting period. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:55 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001415889-24-016087 · form4-06082024_120623.xml · derivative · entry 1 Patni Rajiv · CIK 0001616200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 18:14 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001415889-24-003984 · form4-02152024_110201.xml · derivative · entry 1 Patni Rajiv · CIK 0001616200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2034-02-15 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of February 15, 2024, subject to the Reporting Person's continued service as a member of the Board of Directors of the Issuer as of each such vesting date. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $99.12 | Not disclosed |
DisclosureSEC source: 0000899243-23-019537 · doc4.xml · derivative · entry 2 Patni Rajiv · CIK 0001616200 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 90,000 shares Expires 2033-06-12 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · derivative.exercise_date: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerClass A common stock | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019537 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · shares: The shares represent RSUs, which were to vest as to 11,250 shares on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter. F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 16:26 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right-to-buy) · Derivative | 90,000 | $0.00 Strike: $99.12 | $0.00 |
DisclosureSEC source: 0001209191-23-037021 · doc4.xml · derivative · entry 2 Patni Rajiv · CIK 0001616200 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Class A common stock · 90,000 shares Expires 2033-06-12 F2 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 Class A shares, become exercisable as to 22,500 on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 16:26 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantClass A common stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037021 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 F1 · shares: The shares represent Restricted Stock Units, which vest as to 11,250 shares on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:37 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040356 · doc4.xml · derivative · entry 2 Patni Rajiv · CIK 0001616200 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · derivative.exercise_price: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. F2 · derivative.exercise_date: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. F2 · derivative.expiration_date: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:37 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | $7.89 Strike: $10.11 | $986,250.00 |
DisclosureSEC source: 0001209191-20-040356 · doc4.xml · derivative · entry 1 Patni Rajiv · CIK 0001616200 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2030-02-27 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 19:02 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $10.11 | $0.00 |
DisclosureSEC source: 0001209191-20-015668 · doc4.xml · derivative · entry 2 Patni Rajiv · CIK 0001616200 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-02-27 F2 · derivative.exercise_date: The Options vest as follows: 25% of the shares will vest one year from the Vesting Commencement Date of February 3, 2020, and the remaining shares will vest ratably over the next 36 months. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 19:02 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015668 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Grant of Restrict Stock Units ("RSUs") in consideration of services to be rendered. 1/3 of the RSUs vest on each of March 1, 2021; March 1, 2022; and March 1, 2023, subject to the Reporting Person's Continuous Service under the Issuer's plan documents as of each such date. F1 · balance_after: Grant of Restrict Stock Units ("RSUs") in consideration of services to be rendered. 1/3 of the RSUs vest on each of March 1, 2021; March 1, 2022; and March 1, 2023, subject to the Reporting Person's Continuous Service under the Issuer's plan documents as of each such date. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 16:26 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001209191-19-024240 · doc4.xml · derivative · entry 2 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-04-07 F2 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 16:26 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024240 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,141 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2020, March 20, 2021, March 20, 2022 and March 20, 2023, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 16:45 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 2,374 | $8.00 | $18,992.00 |
DisclosureSEC source: 0001209191-19-020785 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,141 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $7.95 to $8.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 17:51 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 1,252 | $25.94 | $32,476.88 |
DisclosureSEC source: 0001209191-18-021307 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,515 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $25.78 to $25.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 20:50 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 54,750 | $0.00 Strike: $25.66 | $0.00 |
DisclosureSEC source: 0001209191-18-018673 · doc4.xml · derivative · entry 2 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,750 Underlying: Common Stock · 54,750 shares Expires 2028-03-05 F2 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with April 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 20:50 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-018673 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,767 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2019, March 20, 2020, March 20, 2021 and March 20, 2022, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 17:05 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 733 | $17.04 | $12,490.32 |
DisclosureSEC source: 0001209191-17-022340 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,642 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $16.99 to 17.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 18:14 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 41,250 | $0.00 Strike: $16.61 | $0.00 |
DisclosureSEC source: 0001209191-17-004977 · doc4.xml · derivative · entry 2 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 41,250 shares Expires 2027-01-17 F2 · derivative.exercise_date: The shares subject to the option shall become vested according to the following schedule: 1/48th of the shares subject to the option shall vest monthly beginning on February 1, 2017 for 48 months. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 18:14 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-004977 · doc4.xml · nonDerivative · entry 1 Patni Rajiv · CIK 0001616200 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,375 F1 · shares: Represents the grant of restricted stock units that vest 1/4th on each of March 20, 2018, March 20, 2019, March 20, 2020 and March 20, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.